Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.

Andrew Wardley 1 Xavier Pivot 2, 3 Flavia Morales-Vasquez 4 Luis Zetina 5 Maria De Fátima Dias Gaui 6 Douglas Otero Reyes 7 Jacek Jassem 8 Claire Barton 9 Peter Button 10 Veronica Hersberger 9 Antonio Antón Torres 11
1 Cancer research
2 Service d'oncologie Médicale
3 HOTE GREFFON - Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098)
4 Instituto Nacional de Cancerología
5 Hospital Roosevelt
6 Instituto Nacional do Câncer
7 Hospital Center for International Medicine Advanced
8 Medical University of Gdansk
9 F. Hoffmann-La Roche [Basel]
10 Roche Products Pty Ltd
11 Hospital Universitario Miguel Servet
Abstract : PURPOSE To evaluate trastuzumab (H) and docetaxel (T) with or without capecitabine (X) as first-line combination therapy for human epidermal growth factor receptor 2 (HER2) -positive advanced breast cancer. PATIENTS AND METHODS Patients with HER2-positive locally advanced or metastatic breast cancer were randomly assigned to H (8 mg/kg loading; 6 mg/kg every 3 weeks) plus T (75 mg/m(2) in HTX arm, 100 mg/m(2) in HT arm, every 3 weeks) with or without X (950 mg/m(2) twice per day on days 1 to 14 every 3 weeks). The primary end point was overall response rate (ORR). Results In 222 patients, median follow-up was approximately 24 months. ORR was high with both regimens (70.5% with HTX; 72.7% with HT; P = .717); complete response rate was 23.2% with HTX compared with 16.4% with HT. HTX demonstrated significantly longer progression-free survival: median 17.9 months compared with 12.8 months with HT (hazard ratio, 0.72; P = .045), which translates to a gain of around 5 months. Two-year survival probability was 75% with HTX compared with 66% with HT. Febrile neutropenia (27% v 15%) and grade 3/4 neutropenia (77% v 54%) incidences were higher with HT than HTX. Treatment-related grade 3 hand-foot syndrome (17% v < 1%) and grade 3/4 diarrhea (11% v 4%) occurred more commonly with HTX than HT. One case of congestive heart failure occurred in each arm. CONCLUSION HTX is an effective and feasible first-line therapy for HER2-positive locally advanced or metastatic breast cancer, although it should be reserved for patients with good performance status who are not receiving long-term steroids.
Type de document :
Article dans une revue
Journal of Clinical Oncology, American Society of Clinical Oncology, 2010, 28 (6), pp.976-83. 〈10.1200/JCO.2008.21.6531〉
Liste complète des métadonnées
http://www.hal.inserm.fr/inserm-00484605
Contributeur : Philippe Saas <>
Soumis le : mardi 18 mai 2010 - 16:16:27
Dernière modification le : lundi 9 juillet 2018 - 13:12:02

Identifiants

Collections

UNIV-FCOMTE | UMR645

Citation

Andrew Wardley, Xavier Pivot, Flavia Morales-Vasquez, Luis Zetina, Maria De Fátima Dias Gaui, et al.. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.. Journal of Clinical Oncology, American Society of Clinical Oncology, 2010, 28 (6), pp.976-83. 〈10.1200/JCO.2008.21.6531〉. 〈inserm-00484605〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

165

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD